Zimmer Biomet (NYSE:ZBH) Releases Earnings Results

Zimmer Biomet (NYSE:ZBH) posted its quarterly earnings results on Tuesday. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04, FiscalAI reports. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet updated its FY 2026 guidance to 8.300-8.450 EPS.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $89.64 on Tuesday. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59. The business’s 50-day moving average price is $90.02 and its 200 day moving average price is $95.68. Zimmer Biomet has a 52-week low of $84.59 and a 52-week high of $114.44. The firm has a market cap of $17.76 billion, a P/E ratio of 22.19, a PEG ratio of 2.29 and a beta of 0.62.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Tuesday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.76%.

Hedge Funds Weigh In On Zimmer Biomet

Large investors have recently made changes to their positions in the business. Camelot Portfolios LLC raised its holdings in shares of Zimmer Biomet by 1.8% in the 3rd quarter. Camelot Portfolios LLC now owns 11,603 shares of the medical equipment provider’s stock worth $1,143,000 after purchasing an additional 209 shares in the last quarter. Nomura Holdings Inc. grew its position in Zimmer Biomet by 4.6% in the third quarter. Nomura Holdings Inc. now owns 4,923 shares of the medical equipment provider’s stock worth $485,000 after buying an additional 215 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Zimmer Biomet by 0.6% in the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,607 shares of the medical equipment provider’s stock worth $4,000,000 after buying an additional 234 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Zimmer Biomet by 43.4% in the third quarter. Parallel Advisors LLC now owns 895 shares of the medical equipment provider’s stock valued at $88,000 after buying an additional 271 shares in the last quarter. Finally, Public Employees Retirement System of Ohio lifted its position in shares of Zimmer Biomet by 0.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 66,445 shares of the medical equipment provider’s stock valued at $6,545,000 after acquiring an additional 381 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ZBH shares. Robert W. Baird reissued a “neutral” rating and issued a $100.00 target price (down previously from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. Johnson Rice set a $112.00 price target on Zimmer Biomet in a research report on Wednesday, November 5th. Barclays reduced their price objective on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research report on Wednesday, November 5th. Citigroup lowered their price objective on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a research note on Thursday, December 11th. Finally, Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $106.10.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.